Neurologic toxicities of cancer therapies

Current Neurology and Neuroscience Reports

Volumn 6, Issue 3, 2006, Pages 218-226

  Cavaliere, Robert ^a   Schiff, David ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; ACETYLCARNITINE; AMIFOSTINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ASPARAGINASE; CARBAMAZEPINE; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYTARABINE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GLUCONATE CALCIUM; IFOSFAMIDE; LENALIDOMIDE; LEUKEMIA INHIBITORY FACTOR; MAGNESIUM SULFATE; METHOTREXATE; METHYLENE BLUE; NEUROLEPTIC AGENT; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; RECOMBINANT NERVE GROWTH FACTOR; TAMOXIFEN; THALIDOMIDE; UNINDEXED DRUG; VINCRISTINE;

ASEPTIC MENINGITIS; AUTONOMIC NEUROPATHY; BRAIN ATROPHY; BRAIN DISEASE; BRAIN NECROSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CEREBELLUM DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DISABILITY; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG PENETRATION; DRUG WITHDRAWAL; EPILEPTIC STATE; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HUMAN; LEUKOENCEPHALOPATHY; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; OVARY CANCER; PERIPHERAL NEUROPATHY; PSYCHOSIS; QUALITY OF LIFE; REVIEW; SEIZURE; SENSORIMOTOR NEUROPATHY; SENSORY NEUROPATHY; SPINAL CORD DISEASE; STROKE; SYMPTOMATOLOGY;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; NEUROTOXICITY SYNDROMES; NEUROTOXINS;

EID: 33646815345     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-006-0009-8     Document Type: Review

References (86)

1. Leonard GD, Wright MA, Quinn MG, et al.: Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 2005, 5:116.
2. Cersosimo RJ: Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 2005, 39:128-135.
3. Lehky TJ, Leonard GD, Wilson RH, et al.: Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004, 29:387-392.
4. Wilson RH, Lehky T, Thomas RR, et al.: Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002, 20:1767-1774.
5. Grolleau F, Gamelin L, Boisdron-Celle M, et al.: A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001, 85:2293-2297.
6. Webster RG, Brain KL, Wilson RH, et al.: Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol 2005, 146:1027-1039.
7. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC: Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005, 32:51-60.
8. Jamieson SM, Liu J, Connor B, McKeage MJ: Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother Pharmacol 2005, 56:391-399.
9. Gamelin L, Boisdron-Celle M, Delva R, et al.: Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004, 10:4055-4061.
10. Lersch C, Schmelz R, Eckel F, et al.: Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal Cancer 2002, 2:54-58.
11. Penz M, Kornek GV, Raderer M, et al.: Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann Oncol 2001, 12:421-422.
12. Isoardo G, Bergui M, Durelli L, et al.: Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurol Scand 2004, 109:188-193.
13. Giannini F, Volpi N, Rossi S, et al.: Thalidomide-induced neuropathy: a ganglionopathy? Neurology 2003, 60:877-878.
14. Steurer M, Spizzo G, Mitterer M, Gastl G: Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program. Onkologie 2004, 27:150-154.
15. Cavaletti G, Beronio A, Reni L, et al.: Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 2004, 62:2291-2293.
16. Briani C, Zara G, Rondinone R, et al.: Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology 2004, 62:2288-2290.
17. Tosi P, Zamagni E, Cellini C, et al.: Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005, 74:212-216.
18. Bastuji-Garin S, Ochonisky S, Bouche P, et al.: Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol 2002, 119:1020-1026.
19. Koukourakis MI, Simopoulos C, Minopoulos G, et al.: Amifostine before chemotherapy: improved tolerance profile of the subcutaneous over the intravenous route. Clin Cancer Res 2003, 9:3288-3293.
20. Verstappen CC, Postma TJ, Geldof AA, Heimans JJ: Amifostine protects against chemotherapy-induced neurotoxicity: an in vitro investigation. Anticancer Res 2004, 24:2337-2341.
21. Hussain AE, Blakley BW, Nicolas M, Balderston J: Assessment of the protective effects of amifostine against cisplatin-induced toxicity. J Otolaryngol 2003, 32:294-297.
22. Hilpert F, Stahle A, Tome O, et al.: Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/ paclitaxel-based chemotherapy - a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer 2005, 13:797-805.
23. Lorusso D, Ferrandina G, Greggi S, et al.: Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 2003, 14:1086-1093.
24. Openshaw H, Beamon K, Synold TW, et al.: Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res 2004, 10:461-467.
25. Glover D, Ibrahim J, Kirkwood J, et al.: Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). Melanoma Res 2003, 13:619-626.
26. Moore DH, Donnelly J, McGuire WP, et al.: Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. J Clin Oncol 2003, 21:4207-4213.
27. Leong SS, Tan EH, Fong KW, et al.: Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 2003, 21:1767-1774.
28. Rudolph S, Ridwelski K, Kuhn R, Lippert H: Randomised trial with or without amifostine to reduce neurotoxicity side effects under chemotherapy with oxaliplatin, 5-FU. Ann Oncol 2000 11(Suppl 4):154.
29. De Santis S, Pace A, Bove L, et al.: Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res 2000, 6:90-95.
30. Cavaletti G, Bogliun G, Marzorati L, et al.: Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol 2004,15:1439-1442.
31. Cavaletti G, Pezzoni G, Pisano C, et al.: Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor. Neurosci Lett 2002, 322:103-106.
32. Aloe L, Manni L, Properzi F, et al.: Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by cisplatin: behavioral, structural and biochemical analysis. Auton Neurosci 2000, 86:84-93.
33. Tredici G, Braga M, Nicolini G, et al.: Effect of recombinant human nerve growth factor on cisplatin neurotoxicity in rats. Exp Neurol 1999, 159:551-558.
34. Boyle FM, Beatson C, Monk R, et al.: The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin. Cancer Chemother Pharmacol 2001, 48:429-434.
35. Davis ID, Kiers L, MacGregor L, et al.: A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res 2005, 11:1890-1898.
36. Pisano C, Pratesi G, Laccabue D, et al.: Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 2003, 9:5756-5767.
37. Maestri A, De Pasquale Ceratti A, Cundari S, et al.: A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 2005, 91:135-138.
38. Bianchi G, Vitali G, Caraceni A, et al.: Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-l-carnitine. Eur J Cancer 2005, 41:1746-1750.
39. Weigel R, Senn P, Weis J, Krauss JK: Severe complications after intrathecal methotrexate (MTX) for treatment of primary central nervous system lymphoma (PCNSL). Clin Neurol Neurosurg 2004, 106:82-87.
40. Drachtman RA, Cole PD, Golden CB, et al.: Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr Hematol Oncol 2002, 19:319-327.
41. Atra A, Pinkerton CR, Bouffet E, et al.: Acute neurotoxicity in children with advanced stage B-non-Hodgkin's lymphoma and B-acute lymphoblastic leukaemia treated with the United Kingdom children cancer study group 9002/9003 protocols. Eur J Cancer 2004, 40:1346-1350.
42. Brock S, Jennings HR: Fatal acute encephalomyelitis after a single dose of intrathecal methotrexate. Pharmacotherapy 2004, 24:673-676.
43. Lee ST, Kim M: Diffusion-weighted MRIs in an acute leukoencephalopathy following intrathecal chemotherapy. Neurology 2004, 62:832-833.
44. Rollins N, Winick N, Bash R, Booth T: Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. Am J Neuroradiol 2004, 25:1688-1695.
45. Bay A, Oner AF, Etlik O, et al.: Myelopathy due to intrathecal chemotherapy: report of six cases. J Pediatr Hematol Oncol 2005, 27:270-272.
46. Oka M, Terae S, Kobayashi R, et al.: MRI in methotrexate-related leukoencephalopathy: Disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy. Neuroradiology 2003, 45:493-497.
47. Kuker W, Bader P, Herrlinger U, et al.: Transient encephalopathy after intrathekal methotrexate chemotherapy: diffusion-weighted MRI. J Neuro-oncol 2005, 73:47-49.
48. Fisher MJ, Khademian ZP, Simon EM, et al.: Diffusion-weighted MR imaging of early methotrexate-related neurotoxicity in children. Am J Neuroradiol 2005, 26:1686-1689.
49. Gowan GM, Herrington JD, Simonetta AB: Methotrexate-induced toxic leukoencephalopathy. Pharmacotherapy 2002, 22:1183-1187.
50. Lai R, Abrey LE, Rosenblum MK, DeAngelis LM: Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 2004, 62:451-456.
51. Chu WC, Chik KW, Chan YL, et al.: White matter and cerebral metabolite changes in children undergoing treatment for acute lymphoblastic leukemia: longitudinal study with MR imaging and 1H MR spectroscopy. Radiology 2003, 229:659-669.
52. Reddick WE, Glass JO, Helton KJ, et al.: A quantitative MR imaging assessment of leukoencephalopathy in children treated for acute lymphoblastic leukemia without irradiation. AJNR Am J Neuroradiol 2005, 26:2371-2377.
53. Montour-Proulx I, Kuehn SM, Keene DL, et al.: Cognitive changes in children treated for acute lymphoblastic leukemia with chemotherapy only according to the Pediatric Oncology Group 9605 protocol. J Child Neurol 2005, 20:129-133.
54. Kingma A, van Dommelen RI, Mooyaart EL, et al.: Slight cognitive impairment and magnetic resonance imaging abnormalities but normal school levels in children treated for acute lymphoblastic leukemia with chemotherapy only. J Pediatr 2001, 139:413-420.
55. Hill DE, Ciesielski KT, Hart BL, Jung RE: MRI morphometric and neuropsychological correlates of long-term memory in survivors of childhood leukemia. Pediatr Blood Cancer 2004, 42:611-617.
56. Harder H, Holtel H, Bromberg JE, et al.: Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 2004, 62:544-547.
57. Correa DD, DeAngelis LM, Shi W, et al.: Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 2004, 62:548-555.
58. Neuwelt EA, Guastadisegni PE, Varallyay P, Doolittle ND: Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. Am J Neuroradiol 2005, 26:258-265.
59. McAllister LD, Doolittle ND, Guastadisegni PE, et al.: Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000, 46:51-60; discussion 60-61.
60. Hoang-Xuan K, Taillandier L, Chinot O, et al.: Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003, 21:2726-2731.
61. Fliessbach K, Urbach H, Helmstaedter C, et al.: Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Arch Neurol 2003, 60:563-568.
62. Batchelor T, Carson K, O'Neill A, et al.: Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003, 21:1044-1049.
63. Paakko E, Harila-Saari A, Vanionpaa L, et al.: White matter changes on MRI during treatment in children with acute lymphoblastic leukemia: correlation with neuropsychological findings. Med Pediatr Oncol 2000, 35:456-461.
64. Kishi S, Griener J, Cheng C, et al.: Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003, 21:3084-3091.
65. Valik D, Sterba J, Bajciova V, Demlova R: Severe encephalopathy induced by the first but not the second course of high-dose methotrexate mirrored by plasma homocysteine elevations and preceded by extreme differences in pretreatment plasma folate. Oncology 2005, 69:269-272.
66. Chiusolo P, Reddiconto G, Casorelli I, et al.: Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 2002, 13:1915-1918.
67. Linnebank M, Pels H, Kleczar N, et al.: MTX-induced white matter changes are associated with polymorphisms of methionine metabolism. Neurology 2005, 64:912-913.
68. Peyriere H, Poiree M, Cociglio M, et al.: Reversal of neurologic disturbances related to high-dose methotrexate by aminophylline. Med Pediatr Oncol 2001, 36:662-664.
69. Kerbusch T, de Kraker J, Keizer HJ, et al.: Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinetics 2001, 40:41-62.
70. Rieger C, Fiegl M, Tischer J, et al.: Incidence and severity of ifosfamide-induced encephalopathy. Anticancer Drugs 2004, 15:347-350.
71. Nicolao P, Giometto B: Neurological toxicity of ifosfamide. Oncology 2003, 65 (Suppl 2):11-16.
72. Zielinska E, Zubowska M, Misiura K: Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children. J Pediatr Hematol Oncol 2005, 27:582-589.
73. Park IS, Lee HJ, Lee YS, et al.: Ifosfamide-induced encephalopathy with or without using methylene blue. Int J Gynecol Cancer 2005, 15:807-810.
74. Pelgrims J, De Vos F, Van den Brande J, et al.: Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000, 82:291-294.
75. Raj AB, Bertolone SJ, Jaffe N: Methylene blue reversal of ifosfamide-related encephalopathy. J Pediatr Hematol Oncol 2004, 26:116.
76. Turner AR, Duong CD, Good DJ: Methylene blue for the treatment and prophylaxis of ifosfamide-induced encephalopathy. Clin Oncol (R Coll Radiol) 2003, 15:435-439.
77. Courtney MJ, Coffey ET: The mechanism of Ara-C-induced apoptosis of differentiating cerebellar granule neurons. Eur J Neurosci 1999, 11:1073-1084.
78. Geller HM, Cheng KY, Goldsmith NK, et al.: Oxidative stress mediates neuronal DNA damage and apoptosis in response to cytosine arabinoside. J Neurochem 2001, 78:265-275.
79. Ahlemeyer B, Kolker S, Zhu Y, et al.: Cytosine arabinofuranoside-induced activation of astrocytes increases the susceptibility of neurons to glutamate due to the release of soluble factors. Neurochem Int 2003, 42:567-581.
80. Brezden CB, Phillips KA, Abdolell M, et al.: Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000, 18:2695-2701.
81. van Dam FS, Schagen SB, Muller MJ, et al.: Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998, 90:210-218.
82. Ahles TA, Saykin AJ, Furstenberg CT, et al.: Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002, 20:485-493.
83. Tchen N, Juffs HG, Downie FP, et al.: Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003, 21:4175-4183.
84. Wefel JS, Lenzi R, Theriault RL, et al.: The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 2004, 100:2292-2299.
85. Schagen SB, Hamburger HL, Muller MJ, et al.: Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neuro-oncol 2001, 51:159-165.
86. Jenkins V, Shilling V, Fallowfield L, et al.: Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 2004, 13:61-66.